HNSCC tumors are highly immunogenic, with PD-L1 expression found in up to 60% of HNSCC along with elevated levels of intra-tumoral regulatory T cells infiltration [23, 24], thus making immunotherapy particularly attractive in HNSCC. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.